NTLA earnings analysis
What we found in NTLA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Intellia Therapeutics reported Q1 2026 revenues of $15.0 million and a diluted EPS of -$0.81, exceeding analyst estimates. The company announced cash resources expected to fund operations at least into 2028, following a successful public offering that raised approximately $207 million. Cost reductions were observed in R&D expenses, indicating a more sustainable operational approach moving forward.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth
- Q1 2026 revenue reached $15.0 million, a positive change from $14 million in Q1 2025.
- Improved EPS
- Diluted EPS for Q1 2026 at -$0.81, improving from -$0.92 in Q1 2025.
- Strong Cash Position
- Cash, cash equivalents, and marketable securities amounted to $517.2 million as of March 31, 2026.
- Cost Reductions
- R&D expenses significantly decreased by $27.7 million (26%) from Q1 2025.
- Successful Equity Offering
- Raised $33.6 million in Q1 2026 through at-the-market offerings.
- Regulatory Progress
- Received RMAT designation for both nex-z and lonvo-z, expediting potential regulatory review.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Negative Cash Flow
- Operating cash flow was $117.3 million negative in Q1 2026, indicating ongoing cash burn.
- Regulatory Approval Uncertainty
- The company faces uncertainties regarding the approval of lonvo-z and nex-z due to the complex regulatory environment.
- Competition Risks
- Intense competition from other biotech firms targeting similar indications could impact market share.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.81
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads better than the one before it.
What came before.
- 10-K · February 26, 2026
- Intellia positions itself as a pioneer in in vivo CRISPR genome editing with two Phase 3 programs (lonvo-z for HAE and nex-z for ATTR). The company completed enrollment in the HAELO Phase 3 (80 patients) and plans…
- 10-Q · August 7, 2025
- Intellia reported Q2 2025 collaboration revenue of $14.245M, up from $6.957M in Q2 2024, and GAAP diluted loss per share improved to $(0.98) from $(1.52). Operating loss narrowed to $(109.996)M from $(139.043)M…
- 10-Q · November 7, 2024
- Intellia reported collaboration revenue of $9.111M for Q3 2024 (down from $11.992M in Q3 2023) and a net loss of $135.712M (GAAP) or loss per share of $1.34 (improved from $1.38 a year ago). Operating loss widened to…
- 10-Q · August 8, 2024
- Intellia reported Q2 collaboration revenue of $6.957M, down from $13.594M a year earlier and sharply below the prior quarter (~$28.935M). The company recorded an operating loss of $139.043M and GAAP net loss per share…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NTLA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever